- Record: found
- Abstract: not found
- Article: not found
A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY-318).
J. H. Hecht, Aleix Prat, Miklos Pless, Antonio Cubillo, Aitana Calvo, Steven Raman, Jason Chesney, Chunxu Liu, Emily Chan, JR Hecht, A Prat, M Pless
2018
Read this article at
ScienceOpenPublisher
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.